{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:26:45Z","timestamp":1792614405610,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Disseminated intravascular coagulation (DIC) is a frequent complication in patients with sepsis and is associated with increased mortality. Anticoagulant therapy may be appropriate for certain patients with DIC, particularly those with increased disease severity and deficiency in the physiologic anticoagulant antithrombin. We retrospectively analyzed post-marketing survey data from 1562 patients with sepsis-associated DIC and antithrombin activity of 70% or less. All the patients were treated with antithrombin concentrates. Baseline sequential organ failure assessment (SOFA) score, DIC score, and antithrombin activity were assessed. Cox multivariate regression analysis, Kaplan\u2013Meier curve analysis, and receiver operating characteristic (ROC) curve analysis were performed to evaluate the performance of variables used to assess mortality. Furthermore, a decision tree was constructed to classify the risk of 28-day mortality. COX multivariate regression analysis demonstrated a significant association of age, sex, baseline SOFA score, baseline antithrombin activity, and the presence of pneumonia or skin\/soft tissue infection with increased mortality. The area under the curve of SOFA score or antithrombin activity for mortality was 0.700 and 0.614, respectively. Kaplan\u2013Meier analysis demonstrated that mortality was significantly higher in patients with SOFA score\u2009\u2265\u200912 and antithrombin activity\u2009&lt;\u200947%. The decision tree analysis accurately classified the risk of death into high (&gt;\u200940%), medium (40%\u201320%), and low (&lt;\u200920%) categories in 86.1% of the cohort. Twenty eight-day mortality can be strongly predicted using baseline SOFA score, antithrombin activity, infection site, age, and sex as variables in the clinical decision tree for patients with sepsis-associated disseminated intravascular coagulation (DIC).<\/jats:p>","DOI":"10.1038\/s41598-023-49855-y","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T09:02:20Z","timestamp":1702890140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Risk stratification utilizing sequential organ failure assessment (SOFA) score, antithrombin activity, and demographic data in sepsis-associated disseminated intravascular coagulation (DIC)"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0255-4088","authenticated-orcid":false,"given":"Toshiaki","family":"Iba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4044-2674","authenticated-orcid":false,"given":"Cheryl L.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Tanigawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-4962","authenticated-orcid":false,"given":"Jerrold H.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"issue":"3","key":"49855_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jiac.2013.07.006","volume":"20","author":"H Ogura","year":"2014","unstructured":"Ogura, H. et al. Epidemiology of severe sepsis in Japanese intensive care units: A prospective multicenter study. J. Infect. Chemother. 20(3), 157\u2013162 (2014).","journal-title":"J. Infect. Chemother."},{"key":"49855_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.thromres.2019.04.025","volume":"178","author":"S Gando","year":"2019","unstructured":"Gando, S. et al. Role of disseminated intravascular coagulation in severe sepsis. Thromb. Res. 178, 182\u2013188 (2019).","journal-title":"Thromb. Res."},{"issue":"5","key":"49855_CR3","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1055\/s-0037-1616068","volume":"86","author":"FB Taylor Jr","year":"2001","unstructured":"Taylor, F. B. Jr. et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb. Haemost. 86(5), 1327\u20131330 (2001).","journal-title":"Thromb. Haemost."},{"issue":"3","key":"49855_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/01.CCM.0000202209.42491.38","volume":"34","author":"S Gando","year":"2006","unstructured":"Gando, S. et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: Comparing current criteria. Crit. Care Med. 34(3), 625\u2013631 (2006).","journal-title":"Crit. Care Med."},{"issue":"9","key":"49855_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017046","volume":"7","author":"T Iba","year":"2017","unstructured":"Iba, T., Nisio, M. D., Levy, J. H., Kitamura, N. & Thachil, J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: A retrospective analysis of a nationwide survey. BMJ Open. 7(9), e017046 (2017).","journal-title":"BMJ Open."},{"key":"49855_CR6","doi-asserted-by":"publisher","first-page":"1173893","DOI":"10.3389\/fphar.2023.1173893","volume":"14","author":"JJ Huang","year":"2023","unstructured":"Huang, J. J. et al. Effectiveness of early heparin therapy on outcomes in critically ill patients with sepsis-induced coagulopathy. Front. Pharmacol. 14, 1173893 (2023).","journal-title":"Front. Pharmacol."},{"issue":"11","key":"49855_CR7","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1055\/s-0039-1693740","volume":"119","author":"K Yamakawa","year":"2019","unstructured":"Yamakawa, K. et al. Identifying sepsis populations benefitting from anticoagulant therapy: A prospective cohort study incorporating a restricted cubic spline regression model. Thromb. Haemost. 119(11), 1740\u20131751 (2019).","journal-title":"Thromb. Haemost."},{"key":"49855_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.thromres.2019.07.002","volume":"181","author":"T Matsubara","year":"2019","unstructured":"Matsubara, T. et al. Significance of plasma fibrinogen level and antithrombin activity in sepsis: A multicenter cohort study using a cubic spline model. Thromb. Res. 181, 17\u201323 (2019).","journal-title":"Thromb. Res."},{"key":"49855_CR9","doi-asserted-by":"publisher","first-page":"107602961882404","DOI":"10.1177\/1076029618824044","volume":"25","author":"T Iba","year":"2019","unstructured":"Iba, T. et al. Usefulness of measuring changes in SOFA score for the prediction of 28-day mortality in patients with sepsis-associated disseminated intravascular coagulation. Clin. Appl. Thromb. Hemost. 25, 1076029618824044 (2019).","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"8","key":"49855_CR10","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1055\/s-0029-1145256","volume":"34","author":"M Levi","year":"2008","unstructured":"Levi, M., Schouten, M. & van der Poll, T. Sepsis, coagulation, and antithrombin: Old lessons and new insights. Semin. Thromb. Hemost. 34(8), 742\u2013746 (2008).","journal-title":"Semin. Thromb. Hemost."},{"issue":"5","key":"49855_CR11","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.thromres.2015.03.007","volume":"135","author":"T Iba","year":"2015","unstructured":"Iba, T., Saitoh, D., Gando, S. & Thachil, J. The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation. Thromb. Res. 135(5), 897\u2013901 (2015).","journal-title":"Thromb. Res."},{"key":"49855_CR12","doi-asserted-by":"publisher","first-page":"107602962211357","DOI":"10.1177\/10760296221135790","volume":"28","author":"T Akahoshi","year":"2022","unstructured":"Akahoshi, T. et al. Impact of antithrombin activity levels following recombinant antithrombin gamma therapy in patients with sepsis-induced disseminated intravascular coagulation. Clin. Appl. Thromb. Hemost. 28, 10760296221135790 (2022).","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"5 Suppl","key":"49855_CR13","doi-asserted-by":"publisher","first-page":"S325","DOI":"10.1097\/00003246-200205001-00024","volume":"30","author":"SM Opal","year":"2002","unstructured":"Opal, S. M., Kessler, C. M., Roemisch, J. & Knaub, S. Antithrombin, heparin, and heparan sulfate. Crit. Care Med. 30(5 Suppl), S325\u2013S331 (2002).","journal-title":"Crit. Care Med."},{"issue":"6","key":"49855_CR14","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1177\/1076029618757346","volume":"24","author":"M Hayakawa","year":"2018","unstructured":"Hayakawa, M., Yamakawa, K., Kudo, D. & Ono, K. Optimal antithrombin activity threshold for initiating antithrombin supplementation in patients with sepsis-induced disseminated intravascular coagulation: A multicenter retrospective observational study. Clin. Appl. Thromb. Hemost. 24(6), 874\u2013883 (2018).","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"3","key":"49855_CR15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jtha.2022.11.032","volume":"21","author":"T Iba","year":"2023","unstructured":"Iba, T. et al. Communication from the scientific standardization committees of the international society on thrombosis and haemostasis on vascular endothelium-related biomarkers in disseminated intravascular coagulation. J. Thromb. Haemost. 21(3), 691\u2013699 (2023).","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"49855_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1055\/s-2001-18866","volume":"27","author":"B \u00d8sterud","year":"2001","unstructured":"\u00d8sterud, B. & Bj\u00f8rklid, E. The tissue factor pathway in disseminated intravascular coagulation. Semin. Thromb. Hemost. 27(6), 605\u2013617 (2001).","journal-title":"Semin. Thromb. Hemost."},{"issue":"10","key":"49855_CR17","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.3390\/ijms18102200","volume":"18","author":"E Greco","year":"2017","unstructured":"Greco, E., Lupia, E., Bosco, O., Vizio, B. & Montrucchio, G. Platelets and multi-organ failure in sepsis. Int. J. Mol. Sci. 18(10), 2200 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"49855_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.641750","volume":"12","author":"R Wu","year":"2021","unstructured":"Wu, R., Wang, N., Comish, P. B., Tang, D. & Kang, R. Inflammasome-dependent coagulation activation in sepsis. Front. Immunol. 12, 641750 (2021).","journal-title":"Front. Immunol."},{"issue":"1","key":"49855_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/ams2.659","volume":"8","author":"M Egi","year":"2021","unstructured":"Egi, M. et al. The Japanese clinical practice guidelines for management of sepsis and septic shock 2020 (J-SSCG 2020). Acute Med. Surg. 8(1), e659 (2021).","journal-title":"Acute Med. Surg."},{"issue":"1","key":"49855_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12959-022-00388-w","volume":"20","author":"T Tsuchida","year":"2022","unstructured":"Tsuchida, T., Hayakawa, M., Kawahara, S. & Kumano, O. Thrombin generation capacity is enhanced by low antithrombin activity and depends on the activity of the related coagulation factors. Thromb. J. 20(1), 29 (2022).","journal-title":"Thromb. J."},{"issue":"3","key":"49855_CR21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/jth.13946","volume":"16","author":"Y Umemura","year":"2018","unstructured":"Umemura, Y. & Yamakawa, K. Optimal patient selection for anticoagulant therapy in sepsis: An evidence-based proposal from Japan. J. Thromb. Haemost. 16(3), 462\u2013464 (2018).","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"49855_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13054-016-1415-1","volume":"20","author":"K Yamakawa","year":"2016","unstructured":"Yamakawa, K. et al. Benefit profile of anticoagulant therapy in sepsis: A nationwide multicentre registry in Japan. Crit. Care. 20(1), 229 (2016).","journal-title":"Crit. Care."},{"issue":"5","key":"49855_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.004879","volume":"12","author":"M Banerjee","year":"2019","unstructured":"Banerjee, M., Reynolds, E., Andersson, H. B. & Nallamothu, B. K. Tree-based analysis. Circ. Cardiovasc. Qual. Outcomes. 12(5), e004879 (2019).","journal-title":"Circ. Cardiovasc. Qual. Outcomes."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49855-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49855-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49855-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T13:04:57Z","timestamp":1703163897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49855-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["49855"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-49855-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"assertion":[{"value":"21 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.I. participated on advisory boards of Japan Blood Products Organization, Asahi Kasei Pharmaceuticals, and Toray Medical. T.T. is an employee of Japan Blood Products Organization. CLM. has no disclosures. J.H.L. serves on the Steering or Advisory Committees for Merck, Octapharma, Werfen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22502"}}